Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duloxetine vs Generic SSRIs in Severe Depression
NCT00666757Phase 4Completed
- Sponsor
- Eli Lilly and Company
- Start
- May 2008
- Primary completion
- Feb 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of duloxetine in major depressive disorder (MDD) (5 arms), sponsored by Eli Lilly and Company. Primary endpoint: Probability of Remission [16-item Quick Inventory of Depressive Symptomatology (QIDS-SR) Score Less Than or Equal to 5] at 12 weeks. Started May 2008; status: completed.
02
Drugs
duloxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00666757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00666757.